Quantcast

CureLauncher Introduces Personalized Clinical Trial Matching Service

May 29, 2013

Company empowers people to find new treatments that meet their individual health care needs

Bloomfield Hills, Michigan (PRWEB) May 29, 2013

Michigan-based CureLauncher (CureLauncher.com) today formally launched its patent-pending and proprietary clinical trial matching service that quickly and precisely determines the clinical trials that are best aligned with a person´s unique goals and conditions. The personalized service matches people to any of the 10,000 enrolling trials in the U.S. There is no cost associated with the service.

CureLauncher provides easy-to-understand information and supports people throughout the entire process — from considering a clinical trial to scheduling an appointment to meet the trial staff. For those dealing with a chronic disease, CureLauncher is their personal advocate.

Nearly 200 million Americans have a chronic disease such as diabetes, heart disease, asthma or cancer. Less than five percent of them know where to find new treatments available in clinical trials according to the Center for Information & Study on Clinical Research Participation (CISCRP).

“Sadly, very few people are aware how to benefit from these potentially life-changing trials or how to find trials that are right for their individual condition,” said Stephen Goldner, co-founder and CEO of CureLauncher. “CureLauncher redefines the approach to clinical trials by putting people and their families first. We always put the person first and help them find whatever new treatment matches their conditions.”

“No matter what stage of disease, you want to find all the options right from the beginning,” said Dr. Max Wicha, Director of the University of Michigan Comprehensive Cancer Center. “The very best treatment for someone may be in a clinical trial.”

There are nearly 10,000 new clinical trials enrolling in the United States right now. Each trial will be delayed an average of five months due to lack of enrollment according to CISCRP.

“Currently, it can take up to ten years for a lifesaving drug to come to market — a drug that can extend a person´s life when nothing else is working and all options have seemingly been exhausted,” said two-time cancer survivor David Fuehrer, co-founder and president of CureLauncher. “With trial delays due to lack of enrollment, that means people with cancer and other diseases have to wait longer for new treatments. This is time they can´t afford to wait.”

By identifying the best matches for any individual and making the connections, CureLauncher´s mission is to empower people to make a life changing decision while helping bring new treatments to people faster.

TAKING CONTROL

CureLauncher helps solve the industry issues of trial enrollment with its translational database of clinical trials and proprietary matching system to find the best option for any individual–quickly and precisely. Available at no cost, CureLauncher outperforms competing approaches, both in finding more suitable matches and reducing inappropriate ones. CureLauncher generates its revenue from relationships with any clinical trial site unlike Pharmaceutical-funded matching services which only offer information from their own trials.

CureLauncher has trained Relationship Managers who work with individuals or their loved ones. Once matches are identified, CureLauncher staff summarizes these choices in a clear, easy-to-read format that is convenient to share with family, caregivers and doctors. Once a choice is made, CureLauncher will coordinate with the clinical trial so the person can meet their team and learn more.

ABOUT CURELAUNCHER

CureLauncher gives people the power and support to make a life-changing decision. It´s patent-pending matching system helps people find treatment options that are aligned with their unique goals and conditions. Take Control. Know Your OptionsTM. Learn more at http://www.CureLauncher.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10776652.htm


Source: prweb



comments powered by Disqus